Infertility. Female Infertility
Conditions
Interventions
Intervention 1: Intervention group: In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal sal
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Have at least a history of cycle cancellation due to a thin endometrium less than 7 mm following standard hormonal treatment Age 18-45 years Availability of =1 embryo with good quality Normal baseline hormones value including : Testosterone, Progesterone, Prolactin, LH, FSH
Exclusion criteria
Exclusion criteria: Internal genital anomalies Active intrauterine infection ET=7 on the 10th day of cycle History of Asherman syndrome History of cancer History of uterine surgery in past 3 months Intrauterine polyps visible in Transvaginal Ultrasonography Visible intrauterine adhesion Pathospermia in partner Premature ovarian failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endometrial thickness. Timepoint: Baseline (10th day of cycle), and On the day of response to treatment (in case of response) and in case of non-response to treatment on the 18th day of the cycle. Method of measurement: Transvaginal ultrasonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Pregnancy Rate(The number of fetuses that have a heartbeat and are not ectopic). Timepoint: 6-8 of gestational week. Method of measurement: Transvaginal Ultrasonography.;Early pregnancy complications including early miscarriage (miscarriage in less than 12th gestational week) and Ectopic pregnancy. Timepoint: During the first 12 weeks of pregnancy. Method of measurement: Clinical and radiological evolution during 12 weeks of pregnancy.;Implantation rate(The number of gestational sacs to the number of transferred embryos). Timepoint: 6-8 of gestational week. Method of measurement: Transvaginal ultrasonography.;IVF cancellation rate(The number of patients who do not reach enough endometrial thickness for transferring despite maximum treatment). Timepoint: 2 days following the last dose of placebo or growth hormone. Method of measurement: Transvaginal ultrasonography.;Response to treatment (The number of patients that reach at least 7 mm of endometrial thickness). Timepoint: 2 days following the last dose of placebo or growth hormone. Method of measurement: Transvaginal ultrasonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNastaran Zamani Dehkordi
Esfahan University of Medical Sciences
Outcome results
None listed